Michael E. Fitzgerald

Hypnion, Inc. discovered and developed neuroscience drugs. It focused on the development of novel therapeutics for the treatment of central nervous system disorders to serve the underserved markets of sleep and wake-alertness disorders and circadian rhythm abnormalities. The company was founded in 2000 and was headquartered in Lexington, MA.

Part of Takeda Pharmaceutical Co., Ltd., CytoMed, Inc. is a company that develops therapeutics for cancer treatment. The company is based in Cambridge, MA. CytoMed was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on February 12, 1999 for $19.29 million.

Link Medicine Corp. develops disease modifying neurodegenerative therapies. The company was founded by Edward I. Rudman, Peter T. Lansbury, David Neafus and Adam J. Rosenberg in 2005 and is headquartered in Cambridge, MA.

Part of Groupe Limagrain Holding SA, Biotechnica International, Inc. is a company that specializes in agricultural research. The company is based in Shawnee Mission, KS.

W.R. Grace & Co. engages in the production and sale of chemicals and materials. It operates through the Grace Catalysts Technologies and Grace Materials Technologies segments. The Grace Catalysts Technologies segment includes catalysts and related products and technologies used in refining, petrochemical and other chemical manufacturing applications. The Grace Materials Technologies segment consists of specialty materials, including silica-based and silica-alumina-based materials, used in coatings, consumer, industrial, and pharmaceutical applications. The firm specializes in chemical processing, coatings and inks, food and beverage, general industrial, nutraceutical, personal care, pharma, and plastics industries. The company was founded by William Russell Grace in 1854 and is headquartered in Columbia, MD.

Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.